Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Delta-8-THC vs Ondansetron for Chemotherapy-Induced Nausea
NCT00285051Phase 2Terminated
- Sponsor
- Rafa Laboratories
- Start
- Nov 2005
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of delta-8-tetrahydrocannabinol in chemotherapy-induced nausea and vomiting (CINV) (4 arms), sponsored by Rafa Laboratories. Primary endpoint: Visual Analog Scale for Nausea at 4 days. Started Nov 2005; status: terminated.
02
Drugs
delta-8-tetrahydrocannabinol
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00285051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00285051.